EUVIMEDEUVIMED entdecken
Open Access

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant

William C Shropshire iD, Bradley T Endres, Jovan Borjan, Samuel L Aitken iD, William C Bachman, Christi L McElheny, Chin-Ting Wu, Stephanie L Egge, Ayesha Khan, William R Miller iD, Micah M Bhatti, Pranoti Saharasbhojane und 4 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von William C Shropshire und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Ceftazidime, Escherichia coli. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To characterize a blaCMY variant associated with ceftazidime/avibactam resistance from a serially collected Escherichia coli isolate.

Methods

A patient with an intra-abdominal infection due to recurrent E. coli was treated with ceftazidime/avibactam. On Day 48 of ceftazidime/avibactam therapy, E. coli with a ceftazidime/avibactam MIC of >256 mg/L was identified from abdominal drainage. Illumina and Oxford Nanopore Technologies WGS was performed on serial isolates to identify potential resistance mechanisms. Site-directed mutants of CMY β-lactamase were constructed to identify amino acid residues responsible for ceftazidime/avibactam resistance.

Results

WGS revealed that all three isolates were E. coli ST410. The ceftazidime/avibactam-resistant strain uniquely acquired a novel CMY β-lactamase gene, herein called blaCMY-185, harboured on an IncI-γ/K1 conjugative plasmid. The CMY-185 enzyme possessed four amino acid substitutions relative to CMY-2, including A114E, Q120K, V211S and N346Y, and conferred high-level ceftazidime/avibactam resistance with an MIC of 32 mg/L. Single CMY-2 mutants did not confer reduced ceftazidime/avibactam susceptibility. However, double and triple mutants containing N346Y previously associated with ceftazidime/avibactam resistance in other AmpC enzymes, conferred ceftazidime/avibactam MICs ranging between 4 and 32 mg/L as well as reduced susceptibility to the newly developed cephalosporin, cefiderocol. Molecular modelling suggested that the N346Y substitution confers the reduction of avibactam inhibition due to steric hindrance between the side chain of Y346 and the sulphate group of avibactam.

Conclusions

We identified ceftazidime/avibactam resistance in E. coli associated with a novel CMY variant. Unlike other AmpC enzymes, CMY-185 appears to require an additional substitution on top of N346Y to confer ceftazidime/avibactam resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeEscherichia coliHumansbeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsDrug CombinationsPlasmidsMicrobial Sensitivity Tests

Substanzen

Ceftazidimebeta-LactamasesAnti-Bacterial AgentsavibactamAzabicyclo CompoundsDrug Combinations

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Program in Diagnostic Genetics and Genomics, MD Anderson Cancer Center School of Health Professions, Houston, TX, USA.
  • Department of Internal Medicine, Division of Infectious Diseases, Houston Methodist Hospital, Houston, TX, USA.

ORCID-Profile: William C Shropshire, Samuel L Aitken, William R Miller, Akito Kawai, Ryan K Shields, Samuel A Shelburne, Yohei Doi

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Takeda Science Foundation
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Shropshire, W. C., Endres, B. T., Borjan, J., Aitken, S. L., Bachman, W. C., McElheny, C. L., Wu, C. T., Egge, S. L., Khan, A., Miller, W. R., Bhatti, M. M., Saharasbhojane, P., Kawai, A., Shields, R. K., Shelburne, S. A., & Doi, Y. (2023). High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad249

Vancouver

Shropshire WC, Endres BT, Borjan J, Aitken SL, Bachman WC, McElheny CL, et al. High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad249

BibTeX
@article{Shropshire2023,
  author = {Shropshire, William C and Endres, Bradley T and Borjan, Jovan and Aitken, Samuel L and Bachman, William C and McElheny, Christi L and Wu, Chin-Ting and Egge, Stephanie L and Khan, Ayesha and Miller, William R and Bhatti, Micah M and Saharasbhojane, Pranoti and Kawai, Akito and Shields, Ryan K and Shelburne, Samuel A and Doi, Yohei},
  title = {High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad249}
}
Kostenlos starten →